CFO departure
TScan Therapeutics, Inc. discloses CFO departure: Jason A. Amello
TScan Therapeutics, Inc. reported in a Form 8-K filed September 30, 2026 a change involving its Chief Financial Officer, Jason A. Amello, effective November 2026. The filing's own words are quoted below.
In the filing's words
it was agreed that Jason A. Amello would cease to serve as the Company’s Chief Financial Officer and Chrystal Louis, M.D., MPH, would cease to serve as the Company’s Chief Medical Officer.
Verbatim from sec.gov, Item 5.02. We quote departures; we do not characterize them.
| Company | TScan Therapeutics, Inc. (TCRX) |
|---|---|
| Event | Departure |
| Outgoing | Jason A. Amello |
| Effective | November 2026 |
| 8-K filed | September 30, 2026 |
| SEC CIK | 0001783328 |
TScan Therapeutics, Inc. reported this change in a Form 8-K, Item 5.02, filed September 30, 2026. The filing's own words are quoted above.
Sources
- sec.gov · SEC filing, Item 5.02 · accessed 2026-10-01
Something wrong about Jason A. Amello? Send a correction with the primary source.